(9) found that although high ILF2 expression was associated with poorer prognosis in breast cancer, patients with elevated ILF2 levels responded better to anthracycline/paclitaxel neoadjuvant chemotherapy. The gene discussed is ILF2; the disease is breast carcinoma.